



WHO Training Course on Adjuvants and Vaccine Formulation 9 – 13 September 2013, University of Lausanne

Monday, 9 September 2013

	1. Introduction session
9:00 – 9:30	Welcome address Nicolas Collin , University of Lausanne, Switzerland
	Introduction to WHO course Ulrich Früth , World Health Organization, Geneva, Switzerland Maria Lawrenz , University of Lausanne, Switzerland
	2. General aspects of Adjuvants
9:30 – 10:30	Process development of adjuvanted vaccines Martin Friede , World Health Organization, Geneva, Switzerland
10:30 – 11:00	<i>Coffee break</i>
11:00 – 12:00	Past and present of vaccine adjuvants Virgil Schijns , University of Wageningen, The Netherlands
12:00 – 14:00	<i>Lunch</i>
14:00 – 15:00	Clinical evaluation of adjuvanted vaccines Nathalie Garçon , GlaxoSmithKline Biologicals, Brussels, Belgium
15:00 – 15:30	<i>Coffee break</i>
15:30 – 16:30	Discussion: A bright future for adjuvants?

Tuesday, 10 September 2013

9:30 – 10:30	<i>Lab visit</i>
10:30 – 12:00	Importance of adjuvant formulation Martin Friede , World Health Organization, Geneva, Switzerland
12:00 – 14:00	<i>Lunch</i>
	3. Adjuvant systems – part I
14:00 – 15:30	Aluminium salts Erik Lindblad , Brenntag, Frederikssund, Denmark
15:30 – 16:00	<i>Coffee break</i>
16:00 – 17:30	Water-in-oil emulsions Stephane Ascarateil , SEPPIC, Paris, France





WHO Training Course on Adjuvants and Vaccine Formulation 9 – 13 September 2013, University of Lausanne

Wednesday, 11 September 2013

	4. Adjuvant systems – part II
9:00 – 10:30	Liposomes Dennis Christensen , Statens Serum Institute, Copenhagen, Denmark
10:30 – 11:00	<i>Coffee break</i>
11:00 – 12:30	Virosomes Christian Moser , Independent Consultant, Bern, Switzerland
12:30 – 14:00	<i>Lunch</i>
14:00 – 15:30	QS21, ISCOMs and other clinically relevant adjuvants Anita Milicic , University of Oxford, United Kingdom
15:30 – 16:00	<i>Coffee break</i>
18:00 – 22:00	Excursion

Thursday, 12 September 2013

	5. Preclinical aspects
8:30 – 9:00	Preclinical development introduction Eddy Rommel , Rommel Consulting Partners, Jodoigne, Belgium
9:00 – 10:00	Animal models and immunogenicity readout Patrice Dubois , University of Lausanne, Switzerland
10:00 – 10:30	<i>Coffee break</i>
10:30 – 11:30	Safety evaluation Eddy Rommel , Rommel Consulting Partners, Jodoigne, Belgium
	6. Practical exercise I: Case studies
11:30 – 12:30	Parallel sessions Case study 1: Preclinical safety testing Eddy Rommel , Rommel Consulting Partners, Jodoigne, Belgium Case study 2: Preclinical Immunogenicity and Efficacy Patrice Dubois , University of Lausanne, Switzerland
12:30 – 14:00	<i>Lunch</i>
14:00 – 17:00	Parallel sessions - continued
17:00 – 18:00	Presentation of case studies 1 & 2 Eddy Rommel & Patrice Dubois





**WHO Training Course on Adjuvants and Vaccine Formulation
9 – 13 September 2013, University of Lausanne**

Friday, 13 September 2013

	7. Adjuvant systems – part III
8:00 – 9:30	Oil-in-water emulsion adjuvants Ennio de Gregorio , Novartis Vaccines and Diagnostics, Siena, Italy
9:30 – 10:00	<i>Coffee break</i>
10:00 – 11:30	Toll like receptor dependent adjuvants Ennio de Gregorio , Novartis Vaccines and Diagnostics, Siena, Italy
11:30 – 12:30	8. Keynote: Mucosal adjuvants Ali Harandi , University of Gothenburg, Sweden
12:30 – 13:30	<i>Lunch</i>
	9. Practical exercise II: Regulatory challenges of adjuvanted vaccines
13:30 – 14:00	Regulatory aspects Pieter Neels , Vaccine-Advise, Brussels, Belgium
14:00 – 15:00	Parallel sessions Group 1: Industry Group 2: Regulators
15:00 – 15:30	<i>Coffee break</i>
15:30 – 17:30	Panel discussion Moderator: Pieter Neels , Vaccine-Advise, Brussels, Belgium
17:30 – 18:00	10. Evaluation of the course and Certification

